Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Precisio Biotix Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, BASQUILL, SEAN M, who serves as the busiest examiner for the portfolio with 1 pending action. The portfolio's current prosecution is focused within 1 distinct art unit. This concentration means that the immediate success of the company's patent applications depends on the specific examination standards of this unit and the individual examiner assigned.
Because the 1 pending office action is concentrated under BASQUILL, SEAN M, the practitioner should focus on the specific historical allowance rates and procedural preferences of this individual. The presence of only 1 distinct art unit suggests that the company's biotechnology technology is being evaluated under a single set of specialized guidelines. Success in the 1 pending action will require a strategy tailored to the specific requirements of the examiner and the art unit involved in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BASQUILL, SEAN M | 1 | 38.8% | +21.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18600476 | Encapsulation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | BASQUILL, SEAN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18600476 | Encapsulation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | BASQUILL, SEAN M | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18600476 | Encapsulation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | BASQUILL, SEAN M | 1614 | §103§112 | Final Rejection | — | Pending | Mar 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrecisio Biotix Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sean M Basquill has the most, with 1 of Precisio Biotix Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.